Palatin Technologies Inc., of Cranbury, N.J., priced an underwritten public offering of approximately 25.4 million common shares and warrants to purchase approximately 12.7 million additional common shares for expected gross proceeds of $16.5 million. Each unit consisted of one common share and a series J warrant to purchase one-half of an additional share, priced at 65 cents per unit. Canaccord Genuity is sole book-running manager, with Roth Capital Partners as lead manager and Chardan Capital Markets as co-manager. The company recently reported positive phase III data with bremelanotide in premenopausal women diagnosed with hypoactive sexual desire disorder and is seeking a commercialization partner.